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ABSTRACT
Diabetic ketoacidosis (DKA) is a medical emergency which requires prompt management to prevent mortality. Treat-
ment is complicated in end stage renal failure (ESRF) patients due to their altered physiology in sugar metabolism 
and fluid haemodynamics. To date, there are only a few case reports illustrating the presentation and management 
of DKA in ESRF patients and a definite guideline on treatment of DKA in ESRF is seriously lacking. We report here a 
case of an ESRF patient on maintenance haemodialysis, who develops DKA due to missed insulin, and outline our 
successful treatment plan. We hope our reported case report research can further contribute to the knowledge of 
DKA management in ESRF.
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INTRODUCTION
Diabetes ketoacidosis (DKA) is an endocrine emergency, 
defined as a triad of hyperglycemia (blood glucose >11 
mmol/L), ketonaemia (serum ketone ≥ 3 mmol/L or 
ketonuria >2+ on urine dipstick), and acidosis (serum 
bicarbonate <15 mmol/L and/or venous pH <7.3) (1). 
In this article, end stage renal failure (ESRF) is defined 
as dependent on dialysis irregardless of the glomerular 
filtration rate.
DKA is attributed to insulin deficiency and increase 
in stressor hormones causing hyperglycaemia. 
Hyperglycaemia in return, causes osmotic diuresis 
and dehydration. Fatty tissue breakdown occurs as an 
alternative metabolism, releasing ketone and acid into 
the bloodstream.  Mortality of 3.9% due to DKA was 
reported in UK from year 1971 to 1991 (1). The mortality 
rate of DKA in Malaysia setting is higher at 17.6 % (2).
The mainstay therapy for DKA revolves around adequate 
fluid replacement, insulin administration, electrolytes 
correction, and treating the precipitating factor. 
However, in ESRF, especially aneuric one who depend 
on regular dialysis, treatment could pose a challenge 
as they can easily go into fluid overload with fluid 
replacement, insulin tend to remain longer in body due 
to reduced renal excretion, and potassium replacement 
may not be required as per non-dialysis patients. To this 
day, there is no definite guideline on how to manage 
DKA in ESRF patients and judicious clinical assessment 
is required to guide our treatment for this population.
CASE REPORT
A 63-years-old-lady with underlying hypertension, 
dyslipidaemia, and type 2 diabetes mellitus (T2DM), 
which was complicated by diabetic retinopathy and 
nephropathy, had ESRF for almost a year. She had 
minimal urine output, of less than 200 mL daily. 
She had been undergoing haemodialysis via right 
intrajugular catheter regularly three times weekly while 
awaiting fistula creation. She was prescribed on a strict 
fluid restriction of 500ml daily. In November 2018, 
she was admitted for catheter-related blood stream, 
during which she was incidentally diagnosed to have 
a right atrial myxoma. Hence, she was referred to the 
cardiothoracic team for mass excision. On the day she 
was electively admitted for the atrial myxoma surgery, 
she experienced reduce appetite and missed three of 
her usual bolus insulin injection. Her capillary blood 
sugar revealed high index pre-dinner. On examination 
she was not lethargic, not tachypnoeic, euvolaemic, 
afebrile and has no signs of circulatory shock. Her 
random venous glucose was 55.8 mmol/L. Her venous 
blood gas showed pH of 7.328, bicarbonate of 13.8 
and partial carbon dioxide level of 29 mmHg. She had 
minimal urine output on catheterization and urinalysis 
showed the presence of ketone of 2+ and glucose of 3+. 
Her serum ketone was 5.5 mg/dl (normal ketone <1) and 
potassium of 4.3 mmol/l. She was diagnosed to have 
diabetic ketoacidosis. Table 1 summarized her blood 
346
Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346)
Mal J Med Health Sci 16(1): 345-347, Jan 2020
Table I: Summary of blood investigations and treatment regime given to the patient, with an estimated body weight of 60kg
28/12/18
4pm
28/12/18
9.30pm
29/12/18
2am
29/12/18
6am
29/12/18
2pm
29/12/18
5.10pm
30/12/18
1 am
Urea (mmol/l) 22.7 23 21.6 22.3 22.4 10.4 11.9
Na(mmol/l) 124 127 131 135 133 135 136
K (mmol/l) 4.3 3.6 3.1 3.1 4.2 3 4.2
Cl (mmol/l) 85 89 96 98 101 97 98
Creatinine (µmol/l) 409 417 384 399 191 235
Hb (g/dl) 8.4 7.8
Hct (%) 29.3 24.3
Platlet (x109/l) 553 465
WCC (x109/l) 18.4 18.6
Urinalysis Blood trace, uro-
bilinogen trace, 
ketone 2+, pro-
tein 2+, glucose 
3+, leu 1+
Glucose (mmol/l) 55.8 36.5 5.1 19 14 8-11
Blood gas pH 7.328, 
HCO3 13.8, 
BE -8.7
pH 7.315, 
HCO3 21.1, 
BE -4.9
pH 7.317, 
HCO3 21.8, BE 
-4.3
7.39, HCO3 
23.5, BE -1.2
7.372, 
HCO3 
27.4, BE 
1.4
CRP (mg/l) 200
Insulin regime S/C Actrapid 
36 units bolus 
and infusion 
of 11 units for 
1 hour, then 4 
units per hour
Insulin infu-
sion 4 units 
per hour
Insulin withheld Insulin infusion 
1 units per hour
Overlap infusion with basal 
boluses 
S/C Actrapid 6 units pre-
meals and S/C Insulatard 12 
units pre-bed
Fluid regime Normal saline 
1L over 1 hour, 
then 1L over 24 
hours
Normal saline 
1L over 24 
hours
Dextrose 10% 
1L over 24 
hours
Normal saline 
1L over 24 
hours
Normal saline 500mL over 
24 hours
Potassium replace-
ment
1g KCl over 24 
hours
1g KCl over 
24 hours
1g KCl over 1 
hour
Hemodialysis 4 hours HD, UF 
1.5L
parameters and her treatment regime. Total fluid given 
on 28/12/18 was 2L normal saline; on 29/12/18 was 1L 
in total of a mixture of 700mL normal saline and 300 
mL 10% dextrose; and on 30/12/18 was 500mL normal 
saline. Potassium replacement was given one gram 
on 28/12/18 and 2g on 29/12/18, as per requirement. 
Blood culture was taken and she was given intravenous 
amoxicillin-clavulanate to cover for a possible catheter-
related infection. Her blood cultures subsequently came 
back with no growth and the antibiotic was discontinued 
after five days.
DISCUSSION
Diabetes mellitus is a common cause of end stage renal 
failure but it is uncommon for ESRF patients to develop 
DKA. ESRF patients have increased insulin secretion, 
lower insulin sensitivity, reduced renal gluconeogenesis, 
and reduced or absence of urine output precluding 
dehydration (3). Fluid loss from body is usually not from 
osmotic diuresis as these patients may have minimal 
to no urine output. Instead, fluid loss may happen if 
there is gastrointestinal loss. The altered physiology in 
patients with terminal renal impairment often leads to 
minimal symptoms of DKA and eludes early detection. It 
is due to the same reasons above that it is more difficult 
to treat DKA in ESRF, as they are more likely to respond 
to lower doses of insulin, and develop fluid overload 
state with the regular fluid regime prescribed for DKA, 
as fluid deficit may not be as much as in non- ESRF 
patients. There are a few case studies discussing about 
management of DKA and ESRF patients, but definite 
guideline is currently lacking (4). 
The patient above had her DKA resolved within 24 hours 
with a fraction of the regular fluid resuscitation volume 
along with regular monitoring and careful insulin regime. 
Fluid replacement is recommended to be done in small 
boluses and with regular clinical fluid assessment to 
prevent pulmonary oedema and cerebral oedema. 
Frequent serum potassium monitoring is compulsory 
and replacement is only recommended with presence 
of hypokalaemia during pre-haemodialysis. Unlike 
normal population, maintenance potassium is not 
required as ESRF patients tend to have hyperkalaemia. 
Insulin administration is carefully titrated and reduced 
as soon as hyperglycaemia is controlled and ketonaemia 
is resolved. Patients undergoing haemodialysis need 
frequent blood sugar monitoring as they can get 
hypoglycaemic with haemodialysis. Any stressor 
or cause of insulin deficiency must be identified 
immediately and to be corrected as soon as possible. 
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Frequency of haemodialysis in patients with DKA is 
determined by the clinical status of the patient, and 
is affected by the fluid status, acidosis and potassium 
level. The usage of haemodialysis in the treatment of 
DKA is controversial and has not been systematically 
studied in ESRF patients. Traditional urgent indications 
such as pulmonary edema and hyperkaelemia are 
the main reasons for acute dialysis in DKA. Carrying 
out earlier than usual dialysis in patients with DKA 
without clear indications can cause rapid decrease of 
serum tonicity, which can thereotically cause cerebral 
oedema. Administration of sodium bicarbonate in this 
population is not recommended, as this often leads 
to hypernatremia, volume expansion and increased 
osmotic pressure. Gradual reduction of osmolality in 
DKA patient is the key to reduce the chance of developing 
cerebral oedema (5). The key management points for 
managing DKA in ESRF versus normal population is 
outlined in table II. Although the response to therapy 
and mortality of DKA in patients with and without ESRF 
is similar, patients with ESRF were older, presented with 
more severe hyperglycaemia and had longer hospital 
admissions, hence a multidisciplinary team effort consist 
of nephrologist, endocrinologist, physician, primary 
care doctors and diabetic nurse educator are crucial in 
ensuring the best clinical outcome.
CONCLUSION
Altered physiology in patients with ESRF who develops 
DKA causes challenges in the management of the 
endocrine emergency but with judicious use of fluid 
and insulin, as well as careful correction of electrolytes, 
the outcome appears to be favorable. Further reviews 
and analyses are required to develop a guideline on the 
management of DKA in this population.  
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Table II: Differences in management of DKA patients with ESRF ver-
sus normal kidney function
Key differences 
in management
Normal kidney func-
tion patients
ESRF patients
Insulin regime Insulin infusion at one 
unit per kg of body 
weight per hour. After 
DKA resolves, insulin 
regime is altered 
according to sugar 
reading.
Lower rate of insulin infusion 
at <1 unit per kg per hour and 
adjusted according to hourly 
blood capillary sugar reading. 
Monitor closely for hypogly-
caemia. 
Fluid regime Isotonic fluid boluses 
(usually normal saline) 
of one litre for first 
hour, then one litre for 
two hours that follows, 
continued by one litre 
for four hours. Further 
fluid regime depends 
on hydration status of 
patient, boluses can be 
repeated as needed. 
Dextrose fluid can be 
given if random cap-
illary sugar reduced 
below normal on in-
sulin infusion, to solve 
starvation ketosis. 
Isotonic fluid boluses at small-
er doses, usually 250mL each 
time, and can be repeated 
according to fluid status of the 
patient and individual require-
ment. Boluses fluid can be giv-
en more if patient has residual 
urine output. Dextrose fluid 
maintenance can be given if 
capillary blood sugar reduced 
with insulin infusion.
Potassium 
replacement
Maintenance potassi-
um according to daily 
requirement given 
routinely, with replace-
ment of boluses of 
1-2 g KCl if level falls 
below 3.5 mmol/L. 
Maintenance potassium is not 
usually given due to hyperka-
laemia associated with ESRF. 
Replacement is only given if 
it falls below 3.5 mmol/L, and 
given slowly.
Acidosis Monitor acidosis close-
ly. For bicarbonate 
replacement if severe 
acidosis.
Patient is somewhat accus-
tomed to mild acidosis associ-
ated with ESRF. Bicarbonate is 
not given in anuric patient.
